A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment

A korean cancer study group protocol st06-02

Yoon Hee Choi, Sang Cheul Oh, Jun Suk Kim, Seung Hyun Nam, Bong Seog Kim, Sang Hee Cho, Ik Joo Chung, Eun Kee Song, Chang Yeol Yim, Jin Ho Baek, Hei Cheul Jeung, Young Seon Hong, Sung Hyun Yang, Hye Jin Kang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Surgery alone is no longer an adequate standard of care for patients with resectable gastric cancer. Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. Methods Patients with histologically confirmed and measurable advanced gastric cancer who showed a relapse even after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy received docetaxel (35 mg/m2) intravenously on day 1 and 8 plus oxaliplatin (100 mg/m2) intravenously on day 1 every 3 weeks until disease progression or unacceptable toxicity. Results A total of 34 patients with relapsed advanced gastric cancer who had received adjuvant chemotherapy with fluoropyrimidine and/or cisplatin for a median of 6 months (range, 1-48 months) were enrolled in this trial; 22 (64.7 %) patients had been exposed to both agents. Their median age was 58 years (range, 50-68 years). The overall response rate was 55.9 % (95 % confidence interval (CI), 38.3-73.5 %), including 1 complete response and 18 partial responses. At a median follow-up duration of 28.5 months (range, 9.2-50.7 months), the median progression- free survival for all patients was 5.3 months (95 % CI, 4.4-6.1 months) and the median overall survival was 13.8 months (95 % CI, 11.1-16.4 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (47.1 %) and diarrhea (17.6 %), respectively. Five patients (14.7 %) experienced febrile neutropenia. Conclusions Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin- based adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)665-672
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume70
Issue number5
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

oxaliplatin
docetaxel
Chemotherapy
Cisplatin
Stomach Neoplasms
Adjuvant Chemotherapy
Neoplasms
Surgery
Toxicity
Confidence Intervals
Therapeutics
Febrile Neutropenia
Standard of Care
Combination Drug Therapy
Neutropenia

Keywords

  • Docetaxel
  • Oxaliplatin
  • Recurrence
  • Stomach neoplasm

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment : A korean cancer study group protocol st06-02. / Choi, Yoon Hee; Oh, Sang Cheul; Kim, Jun Suk; Nam, Seung Hyun; Kim, Bong Seog; Cho, Sang Hee; Chung, Ik Joo; Song, Eun Kee; Yim, Chang Yeol; Baek, Jin Ho; Jeung, Hei Cheul; Hong, Young Seon; Yang, Sung Hyun; Kang, Hye Jin.

In: Cancer Chemotherapy and Pharmacology, Vol. 70, No. 5, 01.11.2012, p. 665-672.

Research output: Contribution to journalArticle

Choi, Yoon Hee ; Oh, Sang Cheul ; Kim, Jun Suk ; Nam, Seung Hyun ; Kim, Bong Seog ; Cho, Sang Hee ; Chung, Ik Joo ; Song, Eun Kee ; Yim, Chang Yeol ; Baek, Jin Ho ; Jeung, Hei Cheul ; Hong, Young Seon ; Yang, Sung Hyun ; Kang, Hye Jin. / A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment : A korean cancer study group protocol st06-02. In: Cancer Chemotherapy and Pharmacology. 2012 ; Vol. 70, No. 5. pp. 665-672.
@article{dcd7e63d119b4f39a05af8a2300cb279,
title = "A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: A korean cancer study group protocol st06-02",
abstract = "Background Surgery alone is no longer an adequate standard of care for patients with resectable gastric cancer. Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. Methods Patients with histologically confirmed and measurable advanced gastric cancer who showed a relapse even after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy received docetaxel (35 mg/m2) intravenously on day 1 and 8 plus oxaliplatin (100 mg/m2) intravenously on day 1 every 3 weeks until disease progression or unacceptable toxicity. Results A total of 34 patients with relapsed advanced gastric cancer who had received adjuvant chemotherapy with fluoropyrimidine and/or cisplatin for a median of 6 months (range, 1-48 months) were enrolled in this trial; 22 (64.7 {\%}) patients had been exposed to both agents. Their median age was 58 years (range, 50-68 years). The overall response rate was 55.9 {\%} (95 {\%} confidence interval (CI), 38.3-73.5 {\%}), including 1 complete response and 18 partial responses. At a median follow-up duration of 28.5 months (range, 9.2-50.7 months), the median progression- free survival for all patients was 5.3 months (95 {\%} CI, 4.4-6.1 months) and the median overall survival was 13.8 months (95 {\%} CI, 11.1-16.4 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (47.1 {\%}) and diarrhea (17.6 {\%}), respectively. Five patients (14.7 {\%}) experienced febrile neutropenia. Conclusions Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin- based adjuvant chemotherapy.",
keywords = "Docetaxel, Oxaliplatin, Recurrence, Stomach neoplasm",
author = "Choi, {Yoon Hee} and Oh, {Sang Cheul} and Kim, {Jun Suk} and Nam, {Seung Hyun} and Kim, {Bong Seog} and Cho, {Sang Hee} and Chung, {Ik Joo} and Song, {Eun Kee} and Yim, {Chang Yeol} and Baek, {Jin Ho} and Jeung, {Hei Cheul} and Hong, {Young Seon} and Yang, {Sung Hyun} and Kang, {Hye Jin}",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s00280-012-1956-1",
language = "English",
volume = "70",
pages = "665--672",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment

T2 - A korean cancer study group protocol st06-02

AU - Choi, Yoon Hee

AU - Oh, Sang Cheul

AU - Kim, Jun Suk

AU - Nam, Seung Hyun

AU - Kim, Bong Seog

AU - Cho, Sang Hee

AU - Chung, Ik Joo

AU - Song, Eun Kee

AU - Yim, Chang Yeol

AU - Baek, Jin Ho

AU - Jeung, Hei Cheul

AU - Hong, Young Seon

AU - Yang, Sung Hyun

AU - Kang, Hye Jin

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background Surgery alone is no longer an adequate standard of care for patients with resectable gastric cancer. Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. Methods Patients with histologically confirmed and measurable advanced gastric cancer who showed a relapse even after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy received docetaxel (35 mg/m2) intravenously on day 1 and 8 plus oxaliplatin (100 mg/m2) intravenously on day 1 every 3 weeks until disease progression or unacceptable toxicity. Results A total of 34 patients with relapsed advanced gastric cancer who had received adjuvant chemotherapy with fluoropyrimidine and/or cisplatin for a median of 6 months (range, 1-48 months) were enrolled in this trial; 22 (64.7 %) patients had been exposed to both agents. Their median age was 58 years (range, 50-68 years). The overall response rate was 55.9 % (95 % confidence interval (CI), 38.3-73.5 %), including 1 complete response and 18 partial responses. At a median follow-up duration of 28.5 months (range, 9.2-50.7 months), the median progression- free survival for all patients was 5.3 months (95 % CI, 4.4-6.1 months) and the median overall survival was 13.8 months (95 % CI, 11.1-16.4 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (47.1 %) and diarrhea (17.6 %), respectively. Five patients (14.7 %) experienced febrile neutropenia. Conclusions Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin- based adjuvant chemotherapy.

AB - Background Surgery alone is no longer an adequate standard of care for patients with resectable gastric cancer. Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. Methods Patients with histologically confirmed and measurable advanced gastric cancer who showed a relapse even after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy received docetaxel (35 mg/m2) intravenously on day 1 and 8 plus oxaliplatin (100 mg/m2) intravenously on day 1 every 3 weeks until disease progression or unacceptable toxicity. Results A total of 34 patients with relapsed advanced gastric cancer who had received adjuvant chemotherapy with fluoropyrimidine and/or cisplatin for a median of 6 months (range, 1-48 months) were enrolled in this trial; 22 (64.7 %) patients had been exposed to both agents. Their median age was 58 years (range, 50-68 years). The overall response rate was 55.9 % (95 % confidence interval (CI), 38.3-73.5 %), including 1 complete response and 18 partial responses. At a median follow-up duration of 28.5 months (range, 9.2-50.7 months), the median progression- free survival for all patients was 5.3 months (95 % CI, 4.4-6.1 months) and the median overall survival was 13.8 months (95 % CI, 11.1-16.4 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (47.1 %) and diarrhea (17.6 %), respectively. Five patients (14.7 %) experienced febrile neutropenia. Conclusions Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin- based adjuvant chemotherapy.

KW - Docetaxel

KW - Oxaliplatin

KW - Recurrence

KW - Stomach neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84871210725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871210725&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-1956-1

DO - 10.1007/s00280-012-1956-1

M3 - Article

VL - 70

SP - 665

EP - 672

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -